Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Invasive group A streptococcal infections in the Netherlands].
Vinkeles Melchers NVS, Nawijn F, Rümke LW, Dix LML, Vestjens SMT, Hietbrink F, Tjon-Kon-Fat R, Verspui-van der Eijk E, de Gier B, Vlaminckx BJM, Içli C, Quaak MSW, Huijskens EIGW. Vinkeles Melchers NVS, et al. Among authors: de gier b. Ned Tijdschr Geneeskd. 2023 Mar 16;167:D7118. Ned Tijdschr Geneeskd. 2023. PMID: 36928399 Dutch.
Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021.
de Gier B, Andeweg S, Joosten R, Ter Schegget R, Smorenburg N, van de Kassteele J; RIVM COVID-19 surveillance and epidemiology team 1,; Hahné SJ, van den Hof S, de Melker HE, Knol MJ; Members of the RIVM COVID-19 surveillance and epidemiology team. de Gier B, et al. Among authors: de melker he. Euro Surveill. 2021 Aug;26(31):2100640. doi: 10.2807/1560-7917.ES.2021.26.31.2100640. Euro Surveill. 2021. PMID: 34355689 Free PMC article.
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Kristoffersen AB, Machado A, Soares P, Nardone A, Bacci S, Kissling E, Nunes B; VEBIS‐EHR Working Group. Monge S, et al. Among authors: de gier b. Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292. Influenza Other Respir Viruses. 2024. PMID: 38654485 Free PMC article.
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
Huiberts AJ, Hoeve CE, de Gier B, Cremer J, van der Veer B, de Melker HE, van de Wijgert JH, van den Hof S, Eggink D, Knol MJ. Huiberts AJ, et al. Among authors: de gier b. Euro Surveill. 2024 Mar;29(10):2400109. doi: 10.2807/1560-7917.ES.2024.29.10.2400109. Euro Surveill. 2024. PMID: 38456217 Free PMC article.
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.
Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Fabiani M, Mateo-Urdiales A, AlKerwi A, Schmitz S, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Starrfelt J, Nunes B, Caetano C, Derrough T, Nardone A, Monge S; VEBIS-Lot4 working group; VEBIS-Lot 4 working group. Fontán-Vela M, et al. Among authors: de gier b. Euro Surveill. 2024 Jan;29(1):2300670. doi: 10.2807/1560-7917.ES.2024.29.1.2300670. Euro Surveill. 2024. PMID: 38179626 Free PMC article.
Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
van Iersel SCJL, McDonald SA, de Gier B, Knol MJ, de Melker HE, Henri van Werkhoven CH, Hahné SJM; RIVM COVID-19 epidemiology and surveillance team. van Iersel SCJL, et al. Among authors: de gier b. Vaccine. 2023 Jun 13;41(26):3847-3854. doi: 10.1016/j.vaccine.2023.05.018. Epub 2023 May 10. Vaccine. 2023. PMID: 37202273 Free PMC article.
53 results